1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Spravato |
| structure | File | |
| classes | List of String, delimiter: , | NMDA receptor antagonist (uncompetitive) • dissociative |
| mechanism | String | |
| uses | String | Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). |
| starting_dose | String | Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. |
| preparations | String | 28 mg/device (each dose uses 2 devices) |
| fda_max | String | 84 mg per session |
| pill_id | Text | |
| routes | List of String, delimiter: , | Intranasal (under direct medical supervision) |
| onset | String | Within hours of first administration |
| duration | String | Acute effect ~24 hours; cumulative effect builds with repeated dosing |
| halflife | String | ~7-12 hours |
| bioavailability | String | ~48% intranasal |
| pregnancy | String | Avoid; may cause fetal harm |
| legal | String | Rx, Schedule III (US). REMS program required. |
